Proteasome inhibition alleviates prolonged moderate compression-induced muscle pathology

BMC Musculoskeletal Disorders

Volumn 12, Issue , 2011, Pages

  Siu, Parco M ^a   Teng, Bee T ^a   Pei, Xiao M ^a   Tam, Eric W ^a  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ATROGIN 1; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; PROTEASOME; UBIQUITIN; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CYSTEINE PROTEINASE INHIBITOR; FBXO32 PROTEIN, RAT; HEAT SHOCK PROTEIN 70; HSP70 3 PROTEIN, RAT; HSP70-3 PROTEIN, RAT; LEUPEPTIN; MUSCLE PROTEIN; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAROTRAUMA; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; LEG COMPRESSION; MUSCLE INJURY; MUSCLE TISSUE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BLOOD LEVEL; RAT; TIBIALIS ANTERIOR MUSCLE; TIBIALIS POSTERIOR MUSCLE; ANIMAL; DECUBITUS; DRUG ANTAGONISM; METABOLISM; PATHOLOGY; PHYSIOLOGY; PRESSURE; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SOFT TISSUE INJURY; SPRAGUE DAWLEY RAT;

ANIMALS; CYSTEINE PROTEINASE INHIBITORS; FEMALE; HSP70 HEAT-SHOCK PROTEINS; LEUPEPTINS; MODELS, ANIMAL; MUSCLE PROTEINS; MUSCLE, SKELETAL; PRESSURE; PRESSURE ULCER; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SKP CULLIN F-BOX PROTEIN LIGASES; SOFT TISSUE INJURIES; UBIQUITIN;

EID: 79952334660     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-12-58     Document Type: Article

References (56)

1. Assessment and management of chronic pressure ulcers in the elderly. AD Garcia DR Thomas, Med Clin North Am 2006 90 925 944 10.1016/j.mcna.2006.05.018 16962850 (Pubitemid 44331250)
2. Support surfaces for pressure ulcer prevention. N Cullum E McInnes SE Bell-Syer R Legood, Cochrane Database Syst Rev 2004 D001735 15266452
3. The relative contributions of compression and hypoxia to development of muscle tissue damage: an in vitro study. D Gawlitta W Li CW Oomens FP Baaijens DL Bader CV Bouten, Ann Biomed Eng 2007 35 273 284 10.1007/s10439-006-9222-5 17136445 (Pubitemid 46122182)
4. Pressure-related deep tissue injury under intact skin and the current pressure ulcer staging systems. MA Ankrom RG Bennett S Sprigle D Langemo JM Black DR Berlowitz CH Lyder, Adv Skin Wound Care 2005 18 35 42 10.1097/00129334-200501000-00016 15714036
5. National Pressure Ulcer Advisory Panel's updated pressure ulcer staging system. J Black M Baharestani J Cuddigan B Dorner L Edsberg D Langemo ME Posthauer C Ratliff G Taler, Urol Nurs 2007 27 144 50 156 17494455
6. Should we include deep tissue injury in pressure ulcer staging systems? The NPUAP debate. J Donnelly, J Wound Care 2005 14 207 210 15909435
7. Bioengineering models of deep tissue injury. A Gefen, Adv Skin Wound Care 2008 21 30 36 10.1097/01.ASW.0000305403.89737.6c 18156827
8. Suspected deep tissue injury. CA Fleck, Adv Skin Wound Care 2007 20 413 415 10.1097/01.ASW.0000280206.96378.5b 17620743
9. Risk factors for a pressure-related deep tissue injury: a theoretical model. A Gefen, Med Biol Eng Comput 2007 45 563 573 10.1007/s11517-007-0187-9 17486382 (Pubitemid 46902063)
10. Stress resistance in Saccharomyces cerevisiae is strongly correlated with assembly of a novel type of multiubiquitin chain. T Arnason MJ Ellison, Mol Cell Biol 1994 14 7876 7883 7969127 (Pubitemid 24373536)
11. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. L Deng C Wang E Spencer L Yang A Braun J You C Slaughter C Pickart ZJ Chen, Cell 2000 103 351 361 10.1016/S0092-8674(00)00126-4 11057907
12. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. IE Wertz KM O'Rourke H Zhou M Eby L Aravind S Seshagiri P Wu C Wiesmann R Baker DL Boone A Ma EV Koonin VM Dixit, Nature 2004 430 694 699 10.1038/nature02794 15258597 (Pubitemid 39061687)
13. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. MH Glickman A Ciechanover, Physiol Rev 2002 82 373 428 11917093 (Pubitemid 34654457)
14. The role of ubiquitin-proteasome-dependent proteolysis in the remodelling of skeletal muscle. D Taillandier L Combaret MN Pouch SE Samuels D Bechet D Attaix, Proc Nutr Soc 2004 63 357 361 10.1079/PAR2004358 15294055 (Pubitemid 38787490)
15. Signaling mechanisms involved in disuse muscle atrophy. P Zhang X Chen M Fan, Med Hypotheses 2007 69 310 321 10.1016/j.mehy.2006.11.043 17376604 (Pubitemid 46818689)
16. Identification of ubiquitin ligases required for skeletal muscle atrophy. SC Bodine E Latres S Baumhueter VK Lai L Nunez BA Clarke WT Poueymirou FJ Panaro E Na K Dharmarajan ZQ Pan DM Valenzuela TM DeChiara TN Stitt GD Yancopoulos DJ Glass, Science 2001 294 1704 1708 10.1126/science.1065874 11679633 (Pubitemid 33104839)
17. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. MD Gomes SH Lecker RT Jagoe A Navon AL Goldberg, Proc Natl Acad Sci USA 2001 98 14440 14445 10.1073/pnas.251541198 11717410 (Pubitemid 33121410)
18. Molecular signaling pathways regulating muscle proteolysis during atrophy. HA Franch SR Price, Curr Opin Clin Nutr Metab Care 2005 8 271 275 10.1097/01.mco.0000165005.01331.45 15809529 (Pubitemid 40586185)
19. Intermittent reloading attenuates muscle atrophy through modulating Akt/mTOR pathway. M Miyazaki M Noguchi T Takemasa, Med Sci Sports Exerc 2008 40 848 855 10.1249/MSS.0b013e318163275f 18408614
20. Ubiquitin ligases MuRF1 and MAFbx in human skeletal muscle atrophy. L de Palma M Marinelli M Pavan A Orazi, Joint Bone Spine 2008 75 53 57 10.1016/j.jbspin.2007.04.019 17977773
21. Pressure ulcer prevention. RF Edlich KL Winters CR Woodard RM Buschbacher WB Long JH Gebhart EK Ma, J Long Term Eff Med Implants 2004 14 285 304 10.1615/JLongTermEffMedImplants.v14.i4.20 15447627 (Pubitemid 39136211)
22. Pressure ulcers and endothelial dysfunction: is there a link? BD Struck JE Wright, J Nutr Elder 2007 26 105 117 10.1300/J052v26n03-05 18285294 (Pubitemid 351664741)
23. The etiology of pressure ulcers: skin deep or muscle bound? CV Bouten CW Oomens FP Baaijens DL Bader, Arch Phys Med Rehabil 2003 84 616 619 10.1053/apmr.2003.50038 12690603 (Pubitemid 36417665)
24. Etiologic factors in pressure sores: an experimental model. RK Daniel DL Priest DC Wheatley, Arch Phys Med Rehabil 1981 62 492 498 7305643 (Pubitemid 11017128)
25. Differential response of skin and muscle in the experimental production of pressure sores. GT Nola LM Vistnes, Plast Reconstr Surg 1980 66 728 733 10.1097/00006534-198011000-00008 7001518 (Pubitemid 10024906)
26. Histopathology of pressure ulcers as a result of sequential computer-controlled pressure sessions in a fuzzy rat model. R Salcido JC Donofrio SB Fisher EK LeGrand K Dickey JM Carney R Schosser R Liang, Adv Wound Care 1994 7 23 4 26, 28 7889250
27. The ubiquitin-proteasome system and skeletal muscle wasting. D Attaix S Ventadour A Codran D Bechet D Taillandier L Combaret, Essays Biochem 2005 41 173 186 10.1042/EB0410173 16250905 (Pubitemid 41500978)
28. Ubiquitin-protein ligases in muscle wasting. PR Cao HJ Kim SH Lecker, Int J Biochem Cell Biol 2005 37 2088 2097 10.1016/j.biocel.2004.11.010 16125112 (Pubitemid 41206823)
29. The time effect of pressure on tissue viability: investigation using an experimental rat model. MP Kwan EW Tam SC Lo MC Leung RY Lau, Exp Biol Med (Maywood) 2007 232 481 487 17392483 (Pubitemid 46524469)
30. Muscle apoptosis is induced in pressure-induced deep tissue injury. PM Siu EW Tam BT Teng XM Pei JW Ng IF Benzie AF Mak, J Appl Physiol 2009 107 1266 1275 10.1152/japplphysiol.90897.2008 19644027
31. Opposing responses of apoptosis and autophagy to moderate compression in skeletal muscle. BT Teng XM Pei EW Tam IF Benzie PM Siu, Acta Physiol (Oxf) 2010 201 239 254 10.1111/j.1748-1716.2010.02173.x 20670304
32. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. KL Rock C Gramm L Rothstein K Clark R Stein L Dick D Hwang AL Goldberg, Cell 1994 78 761 771 10.1016/S0092-8674(94)90462-6 8087844 (Pubitemid 24294452)
33. Proteasome inhibitor ameliorates severe acute pancreatitis and associated lung injury of rats. X Chen SL Li T Wu JD Liu, World J Gastroenterol 2008 14 3249 3253 10.3748/wjg.14.3249 18506934
34. Evidence for abnormal translational regulation of renal 25-hydroxyvitamin D-1alpha-hydroxylase activity in the hyp-mouse. B Yuan Y Xing RL Horst MK Drezner, Endocrinology 2004 145 3804 3812 10.1210/en.2004-0192 15265826 (Pubitemid 39037568)
35. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. KJ Livak TD Schmittgen, Methods 2001 25 402 408 10.1006/meth.2001.1262 11846609 (Pubitemid 34164012)
36. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. WE Mitch AL Goldberg, N Engl J Med 1996 335 1897 1905 10.1056/NEJM199612193352507 8948566 (Pubitemid 26419198)
37. Tumour necrosis factor blockade did not prevent the increase of muscular muscle RING finger-1 and muscle atrophy F-box in arthritic rats. M Granado AI Martin T Priego A Lopez-Calderon MA Villanua, J Endocrinol 2006 191 319 326 10.1677/joe.1.06931 17065414 (Pubitemid 44756533)
38. Expression patterns of atrogenic and ubiquitin proteasome component genes with exercise: effect of different loading patterns and repeated exercise bouts. A Nedergaard K Vissing K Overgaard M Kjaer P Schjerling, J Appl Physiol 2007 103 1513 1522 10.1152/japplphysiol.01445.2006 17690190 (Pubitemid 350033833)
39. Cooperative control of striated muscle mass and metabolism by MuRF1 and MuRF2. CC Witt SH Witt S Lerche D Labeit W Back S Labeit, EMBO J 2008 27 350 360 10.1038/sj.emboj.7601952 18157088 (Pubitemid 351161651)
40. Gene and protein expression associated with protein synthesis and breakdown in paraplegic skeletal muscle. MJ Drummond EL Glynn HL Lujan SE Dicarlo BB Rasmussen, Muscle Nerve 2008 37 505 513 10.1002/mus.20976 18236467
41. Muscle RING-finger protein-1 (MuRF1) as a connector of muscle energy metabolism and protein synthesis. S Koyama S Hata CC Witt Y Ono S Lerche K Ojima T Chiba N Doi F Kitamura K Tanaka K Abe SH Witt V Rybin A Gasch T Franz S Labeit H Sorimachi, J Mol Biol 2008 376 1224 1236 10.1016/j.jmb.2007.11.049 18222470
42. Burn-induced increase in atrogin-1 and MuRF-1 in skeletal muscle is glucocorticoid independent but downregulated by IGF-I. CH Lang D Huber RA Frost, Am J Physiol Regul Integr Comp Physiol 2007 292 328 R336 16946078
43. Acute alcohol intoxication increases atrogin-1 and MuRF1 mRNA without increasing proteolysis in skeletal muscle. TC Vary RA Frost CH Lang, Am J Physiol Regul Integr Comp Physiol 2008 294 1777 R1789 18401005
44. Induction of MafBx and Murf ubiquitin ligase mRNAs in rat skeletal muscle after LPS injection. MJ Dehoux RP van Beneden L Fernandez-Celemin PL Lause JP Thissen, FEBS Lett 2003 544 214 217 10.1016/S0014-5793(03)00505-2 12782319 (Pubitemid 36628065)
45. Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. G Bonuccelli F Sotgia W Schubert DS Park PG Frank SE Woodman L Insabato M Cammer C Minetti MP Lisanti, Am J Pathol 2003 163 1663 1675 10.1016/S0002-9440(10)63523-7 14507673 (Pubitemid 37175113)
46. Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment. S Assereto S Stringara F Sotgia G Bonuccelli A Broccolini M Pedemonte M Traverso R Biancheri F Zara C Bruno MP Lisanti C Minetti, Am J Physiol Cell Physiol 2006 290 577 C582 10.1152/ajpcell.00434.2005 16192300
47. A proteasome inhibitor effectively prevents mouse heart allograft rejection. H Luo Y Wu S Qi X Wan H Chen J Wu, Transplantation 2001 72 196 202 10.1097/00007890-200107270-00005 11477338 (Pubitemid 32729334)
48. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. L Meng R Mohan BH Kwok M Elofsson N Sin CM Crews, Proc Natl Acad Sci USA 1999 96 10403 10408 10.1073/pnas.96.18.10403 10468620 (Pubitemid 29422570)
49. Inhibition of the proteasome reduces transfer-induced diabetes in nonobese diabetic mice. J Petrovic H Hall R Mehr R Glas P Hoglund, Scand J Immunol 2004 60 134 142 10.1111/j.0300-9475.2004.01473.x 15238082 (Pubitemid 38943060)
50. Role of proteasomes in T cell activation and proliferation. X Wang H Luo H Chen W Duguid J Wu, J Immunol 1998 160 788 801 9551914 (Pubitemid 28049320)
51. Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. TM Zollner M Podda C Pien PJ Elliott R Kaufmann WH Boehncke, J Clin Invest 2002 109 671 679 11877475 (Pubitemid 34204846)
52. Regulation of apoptosis by the ubiquitin and proteasome pathway. C Wojcik, J Cell Mol Med 2002 6 25 48 10.1111/j.1582-4934.2002.tb00309.x 12003667 (Pubitemid 44133981)
53. Programmed cell death and the proteasome. HC Drexler, Apoptosis 1998 3 1 7 10.1023/A:1009604900979 14646512 (Pubitemid 128511999)
54. The role of the ubiquitin-proteasome pathway in apoptosis. RZ Orlowski, Cell Death Differ 1999 6 303 313 10.1038/sj.cdd.4400505 10381632 (Pubitemid 29186874)
55. Quantification and localisation of damage in rat muscles after controlled loading; a new approach to study the aetiology of pressure sores. EM Bosboom CV Bouten CW Oomens HW van Straaten FP Baaijens H Kuipers, Med Eng Phys 2001 23 195 200 10.1016/S1350-4533(01)00034-0 11410384 (Pubitemid 32532061)
56. Compression-induced deep tissue injury examined with magnetic resonance imaging and histology. A Stekelenburg CW Oomens GJ Strijkers K Nicolay DL Bader, J Appl Physiol 2006 100 1946 1954 10.1152/japplphysiol.00889.2005 16484364 (Pubitemid 43845870)